138-14-7
基本信息
甲磺酸除鐵靈
甲磺酸去鐵敏
甲磺酸去鐵胺
去鐵胺甲磺酸鹽
去鐵胺甲磺酸酯
去鐵銨/去鐵敏
去鐵銨 USP標(biāo)準(zhǔn)品
甲磺酸去鐵胺/去鐵胺
DEFEROX胺甲磺酸鹽
desferal
Prestwick_988
desferalmesylate
deferoxaminemesilate
deferoxaminebmesylate
DEFEROXAMINE MESYLATE
monomethanesulfonate(sa
Desferioxamine mesylate
desferrioxaminebmesylate
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
2024/11/08 | 46177 | 甲磺酸去鐵胺 Deferoxamine mesylate, 95% | 138-14-7 | 1g | 3817元 |
2024/11/08 | S5742 | 去鐵銨 Deferoxamine mesylate | 138-14-7 | 25mg | 1041.12元 |
2024/11/08 | S5742 | 去鐵銨 Deferoxamine mesylate | 138-14-7 | 10mM(1mL in DMSO) | 1122.65元 |
常見問題列表
Target | Value |
HIF-1α
() | |
Beta Amyloid
() | |
Ferroptosis
() |
Deferoxamine treatment significantly increases HIF-1α binding under all culture conditions, including hypoxic and high-glucose. The mechanism of deferoxamine is through improving HIF-1α biological function through scavenging oxygen free radicals. Deferoxamine (5 μM) has significant effect on the tumor-associated stromal cells cellular multiplication, and cells die at day 7 after exposure to 50 μM and 100 μM deferoxamine. Deferoxamine (5 μM-100 μM) inhibits the proliferation of BMMSCs, and induces apoptosis of MSCs in a dose-dependent manner. Deferoxamine influences the expression of adhesion proteins on MSCs. Deferoxamine (30, 60, 120?μM) shows lower expression of HIF-1α in a concentration dependent way in AdMSCs.
Deferoxamine (100 mg/kg, i.p.) lowers the mortality rate of subarachnoid hemorrhage (SAH) rat. Deferoxamine (100 mg/kg, i.p.) attenuates Evan’s blue extravasation in cortex, ameliorates the tight junction detachment and preserves the integrity of the base membrane examined in electron microscope at day 3 after SAH. Deferoxamine attenuates degradation of BBB proteins after SAH and significantly reduces ferritin expression at day 3 in the cortex, and improves neurologic behavior and cognitive deficits after experimental. Ten μL of 1 mM deferoxamine-treated wounds display significantly accelerated healing from day 7 onward and heal significantly faster than control-treated wounds in diabetic mice. Deferoxamine-treated wounds and dimethyloxalylglycine-treated wounds heal significantly faster than control-treated wounds in aged mice. In deferoxamine (10 mg/mL)-treated TG mice, there is a decrease in both soluble and insoluble Aβ40 and Aβ42. Both pGSK3β and β-catenin are significantly increased by approximately 50% in the deferoxamine-treated mice.